Biobeat Launches IPO Prospectus After Two Months of Rapid Growth: 251 Articles and 106 Financing Reports Delivering In-Depth Biopharma Insights

In the era of mobile health innovation, VCBeat has spent nearly five years building friendships with thousands of peers dedicated to global healthcare innovation. Hundreds of thousands of professionals in the medical innovation sector have relied on VCBeat to stay informed about developments both in China and abroad. VCBeat is fortunate to have done the right things, with the right people, at the right time.

With the introduction of a series of new drug policies in China, the influx of domestic and international capital, and the large-scale return of talent, the biotechnology sector and innovative drug R&D have entered a phase of vigorous development. Since February, VCBeat has begun to focus closely on the biomedical industry and has assembled a team to launch a new WeChat official account—VCBeat BioMed (WeChat ID: biobeat1).

Since its launch two months ago, VCBeat’s New Medicine channel has published 251 articles, providing comprehensive coverage of the biopharmaceutical sector across multiple dimensions, including industry news, capital markets, innovative biotechnologies, and corporate case studies.

In the recently released report on biopharmaceutical investment and financing data for Q1 2019, we found that the investment and financing data in the biopharmaceutical sector covered by the VCBeat database has surpassed that of media outlets such as Rock Health, StartupHealth, and Evaluate Pharma. To date, within the biopharmaceutical sector alone, the VCBeat New Medicine channel has reported on 106 investment and financing deals within just two months.

According to Evaluate Pharma’s database statistics on financing trends in the biopharmaceutical sector, there were 97 global financing deals totaling $3.5 billion, indicating that the slowdown in investment continues. In contrast, VCBeat’s database recorded 131 financing deals with a total amount of $4.764 billion. Due to differences in data volume, VBInsight has reached a different assessment of industry trends compared to Evaluate Pharma.

Meanwhile, according to VCBeat’s database statistics, there were a total of 131 financing events in the biopharmaceutical sector in Q1 2019, while VCBeat’s New Medicine channel reported on 106 of these within just two months. This means that detailed coverage of most global biopharmaceutical investment and financing events can currently be found on VCBeat’s New Medicine channel. We are also striving to ensure that VCBeat serves as the first domestic news source for an increasing number of global biopharmaceutical investment and financing events.

[Exclusive] Yikelai Biology Completes New Round of Financing Exceeding 100 Million Yuan, Led by Huatai Zijin

[Exclusive] Jinsui Gene Completes Tens of Millions in Series A Financing, Emerging as a New Leader in Genetic Testing and Medical Diagnostic Services

[Exclusive] Kangliming Biotech Secures RMB 300 Million in Series B Funding from CDH Investments and IDG Capital, Advancing Early At-Home Colorectal Cancer Diagnosis for Chinese Residents

China’s pharmaceutical market has become the second largest in the world. Coupled with the encouragement and support of numerous favorable policies in recent years, the Chinese market has become a focal point of intense interest for most biopharmaceutical companies. Meanwhile, China holds global advantages in research within certain biological fields, and the acceleration of external regulatory reforms has created a favorable environment for the development of biopharmaceutical enterprises.

VCBeat is closely monitoring the growth and evolution of these companies, presenting their technological advantages, core teams, and development status to our readers. If your company wishes to be featured by VCBeat, please contact us (WeChat ID: q17730797, Mr. Liu). For investment institutions, this is the place to discover the most innovative companies, cutting-edge technologies, and top-tier teams.

From Obscurity to Industry Darling: Why Burning Rock Biotech, with Total Financing Exceeding RMB 1.3 Billion, Has Become a Hot Favorite Among Investors

This microfluidics company, which shares its origins with Solexa, the pioneer of next-generation sequencing, has garnered interest from Ziniu Fund and Inno Angel.

Mass Spectrometry Combined with Biomaterials: Huijian Technology Brings a New Direction to Liquid Biopsy

Focusing on Unmet Protein Needs in Antibody Drug R&D: How Kaige Bio Rapidly Enters the Market

Technological advancements in the biotechnology sector are indeed progressing at a remarkable pace. In just the past two months, VCBeat Pharma has reported on multiple milestone new drug approvals and market launches. For instance, the first novel therapies for triple-negative breast cancer, small cell lung cancer, and major depressive disorder have successively received FDA approval. Meanwhile, China has also seen the approval of new PD-1 inhibitors and blockbuster biosimilars. VCBeat Pharma has established a news monitoring mechanism to provide timely coverage of these new medications.

By tracking key updates from agencies such as the FDA and NMPA, we promptly identify approval information for blockbuster new drugs. We also monitor content from authoritative journals like Science, Nature, and Cell to report on the industry’s most cutting-edge technologies and news. We are confident that in the near future, we will see more new drugs that are accessible, affordable, and effective. Humanity will progressively add tumors, HIV, Alzheimer’s disease, and various rare diseases to the spectrum of curable conditions.

TGF-β + PD-(L)1 Combination: Multi-Target Combination Therapy for Tumors Will Become the Future Theme

Breaking! FDA Commissioner Scott Gottlieb Submits Resignation

First Immunotherapy for Triple-Negative Breast Cancer! FDA Approves Roche’s Tecentriq for Triple-Negative Breast Cancer

FDA New Drug | Depression Treatment Updated for the First Time in Nearly 50 Years: Janssen’s Nasal Spray Spravato Officially Approved

Artery New Medicine compiles data from the biotechnology sector and insights from expert interviews to produce analytical articles on industry development. Through our writing, we aim to report on trends and conduct in-depth research in the biopharmaceutical field. Our coverage seeks to provide more valuable references for innovative drug R&D companies, investment institutions, and biological experts.

By analyzing investment and financing data in the biopharmaceutical sector for 2018, VCBeat New Medicine compiled a report on the strategic layouts of China’s top ten investment firms in this field. The analysis revealed that antibody drugs, targeted therapies, immunotherapies, and specialized disease areas were their primary focus. This article gained widespread circulation within the industry, as professionals sought to understand the investment logic and styles of these major institutions. Additionally, an article published by VCBeat New Medicine on the development challenges faced by genetic testing companies and strategies to overcome them resonated strongly with industry insiders, prompting many leading figures to share it with comments.

Lilly Asia Ventures, Sequoia China, Legend Capital, HighLight Capital... Which biotech projects did top investment firms invest in during 2018?

Reflections After the Frenzy: Gene Testing Startups, Are You Ready for the Future?

CAR-T Therapy Faces Insurance Reimbursement Challenges in the U.S.: The Key Obstacles Lie Here…

Entering the Harvest Period: Global Investment and Financing Data Report on New Medicine (2014-2018)

All the above content is exclusively presented on the VCBeat New Medicine WeChat Official Account. If you have not yet followed us, please scan the QR code below. We look forward to your subscription.